Bu çeviri hazırlanıyor. Bu süre içinde İngilizce orijinal sürümü gösteriyoruz.
Düzenleme ve hukuk · 28.12.20201 dk okuma
Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors
Yerel otomatik çeviri · Kaynağın orijinal dili
Özet
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Senti Bio ("Senti"), located in South San Francisco, CA.
Kaynağın orijinal dili: Federal Register — All DocumentsOrijinal duyuruyu açın →